Simple Education - Co-registration course - Feb 2021

Prof Javier Escaned is Head of Interventional Cardiology Section at Hospital Clinico San Carlos (Madrid, Spain). He trained as a cardiologist the United Kingdom before moving to the Thoraxcenter / Rotterdam (The Netherlands), where he obtained his PhD degree in 1994. With over 30 years of experience as interventionalist, he regularly serves as live case operator and educationalist in global events. He is author of over 500 PubMed indexed scientific articles (h-index 74) on topics that include complex PCI in multivessel disease, left main and chronic total occlusions. His track record in coronary physiology includes being investigator on pivotal FFR trials like DEFER (1998), collaborator with Justin Davies in the validation and clinical implementation of iFR (since 2010), and developer of new methods for the assessment of microvascular and non-obstructive coronary disease. Editorial work includes two large textbooks (“Coronary Stenosis. Imaging, Structure and Physiology” and “Physiological Assessment of Coronary Stenoses and the Microcirculation) and editorial board positions in scientific journals. Board positions in scientific societies include EuroPCR, EAPCI, EuroCTO and the ESC Working Group of Coronary Pathophysiology and Microcirculation. Additional interest incllude music and phylosophy. He is a recipient of the ESC Silver Medal and the 2022 ESC Andreas Gruentzig Award.

Dr Justin Davies is founder and CEO of Wondr Medical, inventor of iFR, and clinical academic and consultant interventional cardiologist at the National Heart and Lung Institute, Imperial College London.

Dr Sharp qualified from Edinburgh Medical School in 1998. He was appointed as a Consultant Cardiologist at the Royal Devon and Exeter Hospital in 2011, before moving to the University Hospital of Wales, in Cardiff, UK in the summer of 2019, where he is now Honorary Professor of Cardiology. He conducted his early training at the Royal Infirmary of Edinburgh, before moving to London for his senior clinical training. He completed the Milan-Imperial Interventional Cardiology Fellowship programme, having spent a year in San Raffaele and Columbus Hospitals, Milan, Italy, under the tutelage of Professor Antonio Colombo. He also spent three years training in interventional cardiology at St Mary’s Hospital and The Hammersmith Hospital (Imperial College Hospitals) in London. Prof Sharp was awarded an MD postgraduate research degree from the University of Edinburgh for his work on the hypertensive heart and leads a large research programme in Wales. He has an international reputation for leading the development of device-based treatments for hypertension (in particular that of renal denervation) and pulmonary embolism, as well as the advancement of intracoronary imaging and physiology.

Carlo Di Mario is Professor of Cardiology at the University of Florence and Director of the Structural 
Interventional Cardiology Division of the University Hospital Careggi, Florence, Italy. Previous posts included 15 years as Professor of Clinical Cardiology at Imperial College of Sciences, Medicine & Technology, London and Consultant Cardiologist at the Royal Brompton Hospital. Despite his teaching, research and administrative commitments, he maintains an active clinical involvement performing more than 100 PCI per year with special interest in the treatment of calcified lesions, chronic total occlusions, bifurcations, and diffuse disease. He is a regular TAVI operator and certified implanter for the Medtronic Evolut R and Edwards Sapien 3 transcatheter aortic valves. He participated in more than 160 MitraClip implantations in London and Florence and has recently started direct annuloplasty with the CardioBand. Professor Di Mario pioneered the use of intracoronary Doppler, pressure measurement, intravascular ultrasound, optical coherence tomography, and near infrared spectroscopy. He was PI of the OPTICUS trial, failing to demonstrate superiority of IVUS guided stenting, and of the Lipid Rich Plaque study, due to report at TCT 2018. He was Principal Investigator of the DESTINI trial, using Doppler CRF to identify lesions in need of stenting, and of the CARESS in AMI trial, a large multicentre trial showing that patients who receive fibrinolytic therapy for ST-elevation myocardial infarction benefit from early angioplasty. This trial and a subsequent meta-analysis have led to a change in the European Society of Cardiology and AHA/ACC Guidelines for treatment of STEMI patients. He cooperated with Dr Davies to the validation of iFR to assess lesion severity and discriminate the contribution of individual lesions, and with Dr Lyon in the intracoronary delivery of SERCA-2 genes via adenoviral vectors in the CUPID2 trial.

Prof Javier Escaned is Head of Interventional Cardiology Section at Hospital Clinico San Carlos (Madrid, Spain). He trained as a cardiologist the United Kingdom before moving to the Thoraxcenter / Rotterdam (The Netherlands), where he obtained his PhD degree in 1994. With over 30 years of experience as interventionalist, he regularly serves as live case operator and educationalist in global events. He is author of over 500 PubMed indexed scientific articles (h-index 74) on topics that include complex PCI in multivessel disease, left main and chronic total occlusions. His track record in coronary physiology includes being investigator on pivotal FFR trials like DEFER (1998), collaborator with Justin Davies in the validation and clinical implementation of iFR (since 2010), and developer of new methods for the assessment of microvascular and non-obstructive coronary disease. Editorial work includes two large textbooks (“Coronary Stenosis. Imaging, Structure and Physiology” and “Physiological Assessment of Coronary Stenoses and the Microcirculation) and editorial board positions in scientific journals. Board positions in scientific societies include EuroPCR, EAPCI, EuroCTO and the ESC Working Group of Coronary Pathophysiology and Microcirculation. Additional interest incllude music and phylosophy. He is a recipient of the ESC Silver Medal and the 2022 ESC Andreas Gruentzig Award.

Dr Justin Davies is founder and CEO of Wondr Medical, inventor of iFR, and clinical academic and consultant interventional cardiologist at the National Heart and Lung Institute, Imperial College London.

Dr Justin Davies is founder and CEO of Wondr Medical, inventor of iFR, and clinical academic and consultant interventional cardiologist at the National Heart and Lung Institute, Imperial College London.

Dr Sharp qualified from Edinburgh Medical School in 1998. He was appointed as a Consultant Cardiologist at the Royal Devon and Exeter Hospital in 2011, before moving to the University Hospital of Wales, in Cardiff, UK in the summer of 2019, where he is now Honorary Professor of Cardiology. He conducted his early training at the Royal Infirmary of Edinburgh, before moving to London for his senior clinical training. He completed the Milan-Imperial Interventional Cardiology Fellowship programme, having spent a year in San Raffaele and Columbus Hospitals, Milan, Italy, under the tutelage of Professor Antonio Colombo. He also spent three years training in interventional cardiology at St Mary’s Hospital and The Hammersmith Hospital (Imperial College Hospitals) in London. Prof Sharp was awarded an MD postgraduate research degree from the University of Edinburgh for his work on the hypertensive heart and leads a large research programme in Wales. He has an international reputation for leading the development of device-based treatments for hypertension (in particular that of renal denervation) and pulmonary embolism, as well as the advancement of intracoronary imaging and physiology.

Dr Yuetsu Kikuta is a Senior Consultant Cardiologist, Division of Cardiology, Fukuyama Cardiovascular Hospital, Japan. He studied physiology as a Clinical Research Fellow (2015-2017) and a Faculty, Advances in Coronary Physiology under Dr Justin E Davies, MBBS, PhD, Imperial College London who invented iFR. He was the first author of the first-in-men international online iFR pullback GRADIENT registry (JACC CV Intv 2018). He was a co-author and an investigator of the DEFINE FLAIR study which showed noninferiority of iFR to FFR (NEJM 2017). He has written the protocol of and started the first-in-men randomized control trial of iFR-coregistration-guided revascularization compared to FFR-pullback guidance in patients with stable coronary artery disease with Prof. Hitoshi Matsuo at Gifu Heart Centre as PI since 2020. He has served as a core committee member of Japanese national PCI registry since 2018. His early mentor was Dr Hideo Tamai who developed the first human biodegradable coronary stent system (Igaki Tamai stent, Circulation 2000). He graduated from Kyoto University in 2002.

Prof Javier Escaned is Head of Interventional Cardiology Section at Hospital Clinico San Carlos (Madrid, Spain). He trained as a cardiologist the United Kingdom before moving to the Thoraxcenter / Rotterdam (The Netherlands), where he obtained his PhD degree in 1994. With over 30 years of experience as interventionalist, he regularly serves as live case operator and educationalist in global events. He is author of over 500 PubMed indexed scientific articles (h-index 74) on topics that include complex PCI in multivessel disease, left main and chronic total occlusions. His track record in coronary physiology includes being investigator on pivotal FFR trials like DEFER (1998), collaborator with Justin Davies in the validation and clinical implementation of iFR (since 2010), and developer of new methods for the assessment of microvascular and non-obstructive coronary disease. Editorial work includes two large textbooks (“Coronary Stenosis. Imaging, Structure and Physiology” and “Physiological Assessment of Coronary Stenoses and the Microcirculation) and editorial board positions in scientific journals. Board positions in scientific societies include EuroPCR, EAPCI, EuroCTO and the ESC Working Group of Coronary Pathophysiology and Microcirculation. Additional interest incllude music and phylosophy. He is a recipient of the ESC Silver Medal and the 2022 ESC Andreas Gruentzig Award.

Dr Nieves Gonzalo is Consultant Interventional Cardiologist at the Interventional Cardiology Department at Clinico San Carlos University Hospital in Madrid. She obtained her Specialist Certification in Cardiology after training at Clinico San Carlos University Hospital in Madrid. Subsequently, she underwent a research fellowship at Thoraxcenter, Erasmus University Rotterdam (The Netherlands) under the supervision of Professor Patrick Serruys, focused mainly in intracoronary imaging and bioabsorbable stents. In 2010 she obtained her PhD with the thesis “Optical coherence tomography for the assessment of coronary atherosclerosis and vessel response after stent implantation”. Her track record includes over 170 articles indexed in PubMed, as well as book chapters in Interventional Cardiology textbooks. Recent research projects as principal investigator includes a study about the assessment of neoatherosclerosis and its clinical impact in patients with restenosis (RIBS IV and V OCT substudy) and research regarding vessel injury and healing evaluation with different stent platforms evaluated with OCT (VISTA study). Dr Gonzalo is a dedicated educationalist with involvement in many areas of complex PCI, serving currently as Deputy Editor for Eurointervention and Committee Member of EuroPCR.

Dr Sharp qualified from Edinburgh Medical School in 1998. He was appointed as a Consultant Cardiologist at the Royal Devon and Exeter Hospital in 2011, before moving to the University Hospital of Wales, in Cardiff, UK in the summer of 2019, where he is now Honorary Professor of Cardiology. He conducted his early training at the Royal Infirmary of Edinburgh, before moving to London for his senior clinical training. He completed the Milan-Imperial Interventional Cardiology Fellowship programme, having spent a year in San Raffaele and Columbus Hospitals, Milan, Italy, under the tutelage of Professor Antonio Colombo. He also spent three years training in interventional cardiology at St Mary’s Hospital and The Hammersmith Hospital (Imperial College Hospitals) in London. Prof Sharp was awarded an MD postgraduate research degree from the University of Edinburgh for his work on the hypertensive heart and leads a large research programme in Wales. He has an international reputation for leading the development of device-based treatments for hypertension (in particular that of renal denervation) and pulmonary embolism, as well as the advancement of intracoronary imaging and physiology.

Prof Javier Escaned is Head of Interventional Cardiology Section at Hospital Clinico San Carlos (Madrid, Spain). He trained as a cardiologist the United Kingdom before moving to the Thoraxcenter / Rotterdam (The Netherlands), where he obtained his PhD degree in 1994. With over 30 years of experience as interventionalist, he regularly serves as live case operator and educationalist in global events. He is author of over 500 PubMed indexed scientific articles (h-index 74) on topics that include complex PCI in multivessel disease, left main and chronic total occlusions. His track record in coronary physiology includes being investigator on pivotal FFR trials like DEFER (1998), collaborator with Justin Davies in the validation and clinical implementation of iFR (since 2010), and developer of new methods for the assessment of microvascular and non-obstructive coronary disease. Editorial work includes two large textbooks (“Coronary Stenosis. Imaging, Structure and Physiology” and “Physiological Assessment of Coronary Stenoses and the Microcirculation) and editorial board positions in scientific journals. Board positions in scientific societies include EuroPCR, EAPCI, EuroCTO and the ESC Working Group of Coronary Pathophysiology and Microcirculation. Additional interest incllude music and phylosophy. He is a recipient of the ESC Silver Medal and the 2022 ESC Andreas Gruentzig Award.

Dr Justin Davies is founder and CEO of Wondr Medical, inventor of iFR, and clinical academic and consultant interventional cardiologist at the National Heart and Lung Institute, Imperial College London.

Carlo Di Mario is Professor of Cardiology at the University of Florence and Director of the Structural 
Interventional Cardiology Division of the University Hospital Careggi, Florence, Italy. Previous posts included 15 years as Professor of Clinical Cardiology at Imperial College of Sciences, Medicine & Technology, London and Consultant Cardiologist at the Royal Brompton Hospital. Despite his teaching, research and administrative commitments, he maintains an active clinical involvement performing more than 100 PCI per year with special interest in the treatment of calcified lesions, chronic total occlusions, bifurcations, and diffuse disease. He is a regular TAVI operator and certified implanter for the Medtronic Evolut R and Edwards Sapien 3 transcatheter aortic valves. He participated in more than 160 MitraClip implantations in London and Florence and has recently started direct annuloplasty with the CardioBand. Professor Di Mario pioneered the use of intracoronary Doppler, pressure measurement, intravascular ultrasound, optical coherence tomography, and near infrared spectroscopy. He was PI of the OPTICUS trial, failing to demonstrate superiority of IVUS guided stenting, and of the Lipid Rich Plaque study, due to report at TCT 2018. He was Principal Investigator of the DESTINI trial, using Doppler CRF to identify lesions in need of stenting, and of the CARESS in AMI trial, a large multicentre trial showing that patients who receive fibrinolytic therapy for ST-elevation myocardial infarction benefit from early angioplasty. This trial and a subsequent meta-analysis have led to a change in the European Society of Cardiology and AHA/ACC Guidelines for treatment of STEMI patients. He cooperated with Dr Davies to the validation of iFR to assess lesion severity and discriminate the contribution of individual lesions, and with Dr Lyon in the intracoronary delivery of SERCA-2 genes via adenoviral vectors in the CUPID2 trial.

Prof Javier Escaned is Head of Interventional Cardiology Section at Hospital Clinico San Carlos (Madrid, Spain). He trained as a cardiologist the United Kingdom before moving to the Thoraxcenter / Rotterdam (The Netherlands), where he obtained his PhD degree in 1994. With over 30 years of experience as interventionalist, he regularly serves as live case operator and educationalist in global events. He is author of over 500 PubMed indexed scientific articles (h-index 74) on topics that include complex PCI in multivessel disease, left main and chronic total occlusions. His track record in coronary physiology includes being investigator on pivotal FFR trials like DEFER (1998), collaborator with Justin Davies in the validation and clinical implementation of iFR (since 2010), and developer of new methods for the assessment of microvascular and non-obstructive coronary disease. Editorial work includes two large textbooks (“Coronary Stenosis. Imaging, Structure and Physiology” and “Physiological Assessment of Coronary Stenoses and the Microcirculation) and editorial board positions in scientific journals. Board positions in scientific societies include EuroPCR, EAPCI, EuroCTO and the ESC Working Group of Coronary Pathophysiology and Microcirculation. Additional interest incllude music and phylosophy. He is a recipient of the ESC Silver Medal and the 2022 ESC Andreas Gruentzig Award.

Dr Nieves Gonzalo is Consultant Interventional Cardiologist at the Interventional Cardiology Department at Clinico San Carlos University Hospital in Madrid. She obtained her Specialist Certification in Cardiology after training at Clinico San Carlos University Hospital in Madrid. Subsequently, she underwent a research fellowship at Thoraxcenter, Erasmus University Rotterdam (The Netherlands) under the supervision of Professor Patrick Serruys, focused mainly in intracoronary imaging and bioabsorbable stents. In 2010 she obtained her PhD with the thesis “Optical coherence tomography for the assessment of coronary atherosclerosis and vessel response after stent implantation”. Her track record includes over 170 articles indexed in PubMed, as well as book chapters in Interventional Cardiology textbooks. Recent research projects as principal investigator includes a study about the assessment of neoatherosclerosis and its clinical impact in patients with restenosis (RIBS IV and V OCT substudy) and research regarding vessel injury and healing evaluation with different stent platforms evaluated with OCT (VISTA study). Dr Gonzalo is a dedicated educationalist with involvement in many areas of complex PCI, serving currently as Deputy Editor for Eurointervention and Committee Member of EuroPCR.

Dr Mauro Echavarría Pinto is an Interventional cardiologist and currently works at “ISSSTE“ General Hospital in Querétaro, México. He trained clinically in the National Institutes of Health, in Mexico City, and in Hospital Clínico San Carlos, in Madrid, Spain. He holds a MSc degree in Research Methodology, Design and Statistics in Health Sciences from the Autonomous University of Barcelona, Spain, and a PhD from the University of Amsterdam, The Netherlands. He is an author of >50 peer-reviewed manuscripts mostly focused on the use of coronary physiology to guide the treatment of ischaemic heart disease.

Dr Sharp qualified from Edinburgh Medical School in 1998. He was appointed as a Consultant Cardiologist at the Royal Devon and Exeter Hospital in 2011, before moving to the University Hospital of Wales, in Cardiff, UK in the summer of 2019, where he is now Honorary Professor of Cardiology. He conducted his early training at the Royal Infirmary of Edinburgh, before moving to London for his senior clinical training. He completed the Milan-Imperial Interventional Cardiology Fellowship programme, having spent a year in San Raffaele and Columbus Hospitals, Milan, Italy, under the tutelage of Professor Antonio Colombo. He also spent three years training in interventional cardiology at St Mary’s Hospital and The Hammersmith Hospital (Imperial College Hospitals) in London. Prof Sharp was awarded an MD postgraduate research degree from the University of Edinburgh for his work on the hypertensive heart and leads a large research programme in Wales. He has an international reputation for leading the development of device-based treatments for hypertension (in particular that of renal denervation) and pulmonary embolism, as well as the advancement of intracoronary imaging and physiology.

Dr. Bruce Samuels is an interventional cardiologist on staff at Cedars-Sinai Medical Center (CSMC) in Los Angeles, California. Dr. Samuels completed his medical studies at Albert Einstein College of Medicine in New York before returning to Southern California to complete his residency and chief residency in Internal Medicine at Harbor-UCLA Medical Center. At CSMC, he trained in both general and interventional cardiology before joining the medical staff there. In addition to his clinical practice in coronary intervention, Dr. Samuels has actively participated in numerous interventional trials including IVUS guided therapy, coronary physiology and microvascular disease. He is also working closely with the Barbra Streisand Women’s Heart Center based at CSMC, working as an interventionalist in the active coronary reactivity research there. As co-chair of a 30-day readmissions task force, he has helped to shape policy for CSMC in its efforts to improve quality delivery of care. He has frequently been invited as faculty to many scientific meetings and is a sought after speaker for numerous peer educational platforms. Dr. Samuels is a fellow of the American College of Cardiology and is Board Certified in Internal Medicine, Cardiovascular Diseases, and Interventional Cardiology. He is married with three sons; his outside interests include contemporary art and long distance running.

Carlo Di Mario is Professor of Cardiology at the University of Florence and Director of the Structural 
Interventional Cardiology Division of the University Hospital Careggi, Florence, Italy. Previous posts included 15 years as Professor of Clinical Cardiology at Imperial College of Sciences, Medicine & Technology, London and Consultant Cardiologist at the Royal Brompton Hospital. Despite his teaching, research and administrative commitments, he maintains an active clinical involvement performing more than 100 PCI per year with special interest in the treatment of calcified lesions, chronic total occlusions, bifurcations, and diffuse disease. He is a regular TAVI operator and certified implanter for the Medtronic Evolut R and Edwards Sapien 3 transcatheter aortic valves. He participated in more than 160 MitraClip implantations in London and Florence and has recently started direct annuloplasty with the CardioBand. Professor Di Mario pioneered the use of intracoronary Doppler, pressure measurement, intravascular ultrasound, optical coherence tomography, and near infrared spectroscopy. He was PI of the OPTICUS trial, failing to demonstrate superiority of IVUS guided stenting, and of the Lipid Rich Plaque study, due to report at TCT 2018. He was Principal Investigator of the DESTINI trial, using Doppler CRF to identify lesions in need of stenting, and of the CARESS in AMI trial, a large multicentre trial showing that patients who receive fibrinolytic therapy for ST-elevation myocardial infarction benefit from early angioplasty. This trial and a subsequent meta-analysis have led to a change in the European Society of Cardiology and AHA/ACC Guidelines for treatment of STEMI patients. He cooperated with Dr Davies to the validation of iFR to assess lesion severity and discriminate the contribution of individual lesions, and with Dr Lyon in the intracoronary delivery of SERCA-2 genes via adenoviral vectors in the CUPID2 trial.

Prof. Constantin von zur Mühlen is heading the interventional cardiology at the Department of Cardiology and Angiologiy I, University Heart Center Freiburg-Bad Krozingen, Germany. His special interests include complex coronary interventions guided by physiology and intracoronary imaging, and structural interventions with a focus on TAVI. Furthermore, he is involved in the upcoming field of robotic-guided interventions, focusing on the combination of established coronary interventional strategies with robotics. He has also served as speaker, faculty member, operator and facilitator in several interventional cardiology meetings.

Dr Mauro Echavarría Pinto is an Interventional cardiologist and currently works at “ISSSTE“ General Hospital in Querétaro, México. He trained clinically in the National Institutes of Health, in Mexico City, and in Hospital Clínico San Carlos, in Madrid, Spain. He holds a MSc degree in Research Methodology, Design and Statistics in Health Sciences from the Autonomous University of Barcelona, Spain, and a PhD from the University of Amsterdam, The Netherlands. He is an author of >50 peer-reviewed manuscripts mostly focused on the use of coronary physiology to guide the treatment of ischaemic heart disease.

Carlo Di Mario is Professor of Cardiology at the University of Florence and Director of the Structural 
Interventional Cardiology Division of the University Hospital Careggi, Florence, Italy. Previous posts included 15 years as Professor of Clinical Cardiology at Imperial College of Sciences, Medicine & Technology, London and Consultant Cardiologist at the Royal Brompton Hospital. Despite his teaching, research and administrative commitments, he maintains an active clinical involvement performing more than 100 PCI per year with special interest in the treatment of calcified lesions, chronic total occlusions, bifurcations, and diffuse disease. He is a regular TAVI operator and certified implanter for the Medtronic Evolut R and Edwards Sapien 3 transcatheter aortic valves. He participated in more than 160 MitraClip implantations in London and Florence and has recently started direct annuloplasty with the CardioBand. Professor Di Mario pioneered the use of intracoronary Doppler, pressure measurement, intravascular ultrasound, optical coherence tomography, and near infrared spectroscopy. He was PI of the OPTICUS trial, failing to demonstrate superiority of IVUS guided stenting, and of the Lipid Rich Plaque study, due to report at TCT 2018. He was Principal Investigator of the DESTINI trial, using Doppler CRF to identify lesions in need of stenting, and of the CARESS in AMI trial, a large multicentre trial showing that patients who receive fibrinolytic therapy for ST-elevation myocardial infarction benefit from early angioplasty. This trial and a subsequent meta-analysis have led to a change in the European Society of Cardiology and AHA/ACC Guidelines for treatment of STEMI patients. He cooperated with Dr Davies to the validation of iFR to assess lesion severity and discriminate the contribution of individual lesions, and with Dr Lyon in the intracoronary delivery of SERCA-2 genes via adenoviral vectors in the CUPID2 trial.

Dr. Bruce Samuels is an interventional cardiologist on staff at Cedars-Sinai Medical Center (CSMC) in Los Angeles, California. Dr. Samuels completed his medical studies at Albert Einstein College of Medicine in New York before returning to Southern California to complete his residency and chief residency in Internal Medicine at Harbor-UCLA Medical Center. At CSMC, he trained in both general and interventional cardiology before joining the medical staff there. In addition to his clinical practice in coronary intervention, Dr. Samuels has actively participated in numerous interventional trials including IVUS guided therapy, coronary physiology and microvascular disease. He is also working closely with the Barbra Streisand Women’s Heart Center based at CSMC, working as an interventionalist in the active coronary reactivity research there. As co-chair of a 30-day readmissions task force, he has helped to shape policy for CSMC in its efforts to improve quality delivery of care. He has frequently been invited as faculty to many scientific meetings and is a sought after speaker for numerous peer educational platforms. Dr. Samuels is a fellow of the American College of Cardiology and is Board Certified in Internal Medicine, Cardiovascular Diseases, and Interventional Cardiology. He is married with three sons; his outside interests include contemporary art and long distance running.